Back to Hematology
Hematologyv2016Evidence-Based

Multiple Myeloma Response Criteria (IMWG)

Evaluates disease response in multiple myeloma according to International Myeloma Working Group (IMWG) criteria including Complete Response, Partial Response, and Progressive Disease categories.

Clinical Input Parameters

%
Range: 0 — 100 %
Range: 0.01 — 1000
%
Range: 0 — 100 %
mg
Range: 0 — 10000 mg
%
Range: 0 — 100 %
Clinical Assessment
Awaiting Parameters
response category
—Points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Multiple Myeloma Response Criteria (IMWG) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

IMWG Response Assessment: Based on immunofixation results, bone marrow plasma cell percentage, M protein levels, soft tissue plasmacytomas, free light chain ratio, and clonal cell presence to determine response category (sCR, CR, VGPR, PR, SD, or PD)

Clinical Pearls & Practice Notes

  • International Myeloma Working Group (IMWG) consensus criteria for response assessment
  • Stringent CR requires all CR criteria plus normal FLC ratio and absence of clonal cells
  • Complete Response requires negative immunofixation and <5% bone marrow plasma cells
  • VGPR requires M component detectable by immunofixation but not electrophoresis
  • Partial Response requires ≥50% reduction in serum M protein
  • Stable Disease is defined as not meeting criteria for other response categories
  • Progressive Disease requires 25% increase from lowest response value
  • Responses should be confirmed on two consecutive assessments
  • Used primarily in clinical trials and research settings
  • Helps standardize response assessment across institutions
  • Free light chain ratio normal range is 0.26-1.65
  • Bone marrow plasma cells <5% required for Complete Response
  • Soft tissue plasmacytomas must disappear for Complete Response
  • Immunofixation is more sensitive than electrophoresis
  • Urine M protein <100 mg per 24 hours for VGPR
  • Serum M protein reduction ≥90% for VGPR
  • Plasmacytoma reduction ≥50% required for Partial Response
  • Assessment frequency should be consistent with clinical protocols
  • Minimal residual disease (MRD) assessment may provide additional information
  • Response criteria may be modified based on evolving evidence
  • Clinical significance of response depth varies by patient population
  • Integration with survival outcomes guides treatment decisions

Evidence & Literature Citations

  1. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
  2. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-73. doi: 10.1038/sj.leu.2404284.
  3. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus guidelines for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-5. doi: 10.1182/blood-2010-10-299487.

Score Interpretation Ranges

Stringent Complete Response (sCR)1 – 1 pts

Best possible response

Complete Response (CR)2 – 2 pts

Complete response

Very Good Partial Response (VGPR)3 – 3 pts

Very good partial response

Partial Response (PR)4 – 4 pts

Partial response

Stable Disease (SD)5 – 5 pts

Stable disease

Progressive Disease (PD)6 – 6 pts

Disease progression

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.